Akebia Therapeutics (AKBA) Depreciation & Amortization (CF) (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $328000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 4.46% year-over-year to $328000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 9.14% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 13.2% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $328000.0, up from $321000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for AKBA reached as high as $417000.0 in Q1 2022 and fell as low as $314000.0 in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $370470.6 across 5 years, with a median of $394000.0 in 2023.
• Across the five-year window, Depreciation & Amortization (CF) dropped 21.0% in 2025 and gained 4.46% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $408000.0 in 2022, then retreated by 3.43% to $394000.0 in 2023, then fell by 14.97% to $335000.0 in 2024, then retreated by 4.18% to $321000.0 in 2025, then advanced by 2.18% to $328000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $328000.0 in Q1 2026, $321000.0 in Q4 2025, and $318000.0 in Q3 2025.